Cencora, Inc. (NYSE:COR) Shares Sold by Jump Financial LLC

Jump Financial LLC lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 96.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,341 shares of the company's stock after selling 83,228 shares during the quarter. Jump Financial LLC's holdings in Cencora were worth $751,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Cencora in the 4th quarter worth $478,309,000. Raymond James Financial Inc. acquired a new stake in shares of Cencora in the 4th quarter worth $322,460,000. Invesco Ltd. boosted its position in shares of Cencora by 20.4% in the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after purchasing an additional 550,246 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Cencora by 140.6% in the 4th quarter. Renaissance Technologies LLC now owns 550,700 shares of the company's stock worth $123,731,000 after purchasing an additional 321,800 shares in the last quarter. Finally, Amundi boosted its position in shares of Cencora by 30.8% in the 4th quarter. Amundi now owns 1,338,710 shares of the company's stock worth $318,385,000 after purchasing an additional 314,846 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Activity

In related news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock worth $13,580,967 in the last quarter. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Performance

Cencora stock traded up $1.85 during mid-day trading on Monday, hitting $287.75. The company had a trading volume of 1,334,120 shares, compared to its average volume of 1,522,104. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The company's fifty day moving average is $268.94 and its 200-day moving average is $250.00. The company has a market capitalization of $55.80 billion, a price-to-earnings ratio of 40.93, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. Cencora's dividend payout ratio (DPR) is 31.29%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on COR shares. Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. Bank of America raised their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and an average target price of $284.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.